VS
RESPONSE AFTER TREATMENT
FALSE POSITIVE
PROTOCOL SEQUENCE
BEST VALUE COMPARATOR
(Androgen Deprivation=AD)
PATIENT
CT
BS
MRI
ChoPET/CT
BVC/Treatment
1
0
0
0
2
2 Abiraterone
2
0
0
1
2
1-SABR
3
0
4
3
5
5 AD
4
0
0
0
0
0
5
0
0
0
0
0
6
0
1
3
1
1-SABR
7
0
0
0
2
2-SABR
8
0
0
2
>5
5 AD
9
0
0
0
1
1-SABR
10
0
0
0
0
0
11
0
0
0
2
2-SABR
12
0
2
2
0
2
Denosumab
+AD
13
0
1
0
0
0
14
0
4
0
2
2
Zoledronic acid+AD
15
0
0
0
1
0
16
0
0
0
1
0
17
0
2
0
0
0
18
0
0
3
3
3 Abiraterone
19
0
4
1
2
1 Refuse Control
20
0
0
1
6
5 AD
21
0
0
1
4
4 AD
.
22
0
0
2
0
0
23
0
2
2
5
5 AD
24
0
2
0
>5
5 AD
25
0
0
1
1
1- SABR
26
0
1
1
2
1- SABR
27
0
0
0
1
0 (
ThyroidSurgery)
28
0
6
7
>5
5 AD
29
0
0
2
1
1 AD
Cho-PET/CT
VALUE% CI 95%
MRI
VALUE% CI95%
SENSITIVITY
88.64
78,12- 99,15
13,64
2,36- 24,91
SPECIFICITY
92.86
75.80-100.00
100.00
96,43- 100.00
PPV
97,50
91.41- 100.00
100.00
91.67- 100.00
NPV
72.22
48.75- 95.69
26.92
13,91-39,94
LYMPH-NODE METASTASES k: 0.143
Cho-PET/CT
VALUE% CI 95%
MRI
VALUE% IC 95%
BONE SCAN
VALUE% CI 95%
SENSITIVITY
90.00
74,35- 100.00
75.00
53.52- 96.48
85.00
66.85- 100.00
SPECIFICITY
85.71
68,37- 100.00
68.18
46.45- 89.92
51.85
31.15- 72.55
PPV
85,71
68,37- 100.00
68.18
46.45- 89.92
56.67
37.27- 76.07
NPV
90.00 74,35-100.00
75.00
53.52- 96.48
82.35
61.29- 100.00
BONES METASTASES
Cho-PET/CT
VALUE% CI 95%
MRI
VALUE% CI 95%
BONE SCAN
VALUE% CI 95%
SENSITIVIY
95.74 88,91-100.00
44,44 30.27-58,62
29,17 15.27-43.07
SPECIFICITY
60.00 24,64-95.36
63,64 30.66-96.91
46.15 15,21-77,1
PPV
91.84 83,15-100.00
85,71 70,97-100.00
66.67 44.12-89,21
NPV
75.00 71,71-93,21
18.93 4.95-32.89
15.00 2,68-27,32
DIAGNOSTIC ANALYSIS
•
18FCho-PET/CT: lesiones en 16 p. no presentes en MRI. Concordancia en 7.
En 3 casos lesiones MR y no en PET.
•
Κ=0.1
Mala Correlación.
•
BVC 10 p. Met. Oseas y 14 ganglionares. 8 SBRT.
•
Sensibilidad y Especificidad NO Comparables.
•
La prueba mejor para BVA: 18FCho-PET/CT.
•
No hay concordancia entre ambas pruebas. PET permite detectar
lesiones no sign. en MRI (MTG).
•
Concordancia en Met. Óseas en SC/RC y NO en MTG
.
•
El seguimiento de la SBRT
PET/CT Colina
.
